We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-0.34%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
-$21.2M
Cap. Flow
+$40.7M
Cap. Flow %
1.55%
Top 10 Hldgs %
39.68%
Holding
190
New
18
Increased
27
Reduced
27
Closed
13

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$47.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$18.8M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.7M
5
PFE icon
Pfizer
PFE
+$13.7M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$47.2M
2
SYK icon
Stryker
SYK
+$24.6M
3
ZBH icon
Zimmer Biomet
ZBH
+$24M
4
HUM icon
Humana
HUM
+$20.2M
5
UNH icon
UnitedHealth
UNH
+$17.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.54%
2 Real Estate 2.01%
3 Industrials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
151
Sutro Biopharma
STRO
$416M
$454K 0.02%
9,835
-4,918
-33% -$312K
NVAX icon
152
Novavax
NVAX
$1.22B
$442K 0.02%
63,800
– –
AFMD
153
DELISTED
Affimed
AFMD
$437K 0.02%
58,604
– –
CYH icon
154
Community Health Systems
CYH
$412M
$433K 0.02%
88,335
– –
TCRX icon
155
TScan Therapeutics
TCRX
$47.3M
$420K 0.02%
200,000
– –
MOR
156
DELISTED
MorphoSys AG American Depositary Shares
MOR
$323K 0.01%
81,867
– –
ALT icon
157
Altimmune
ALT
$583M
$317K 0.01%
+75,000
New +$891K
ALXO icon
158
ALX Oncology
ALXO
$260M
$299K 0.01%
66,211
– –
RPTX
159
DELISTED
Repare Therapeutics
RPTX
$287K 0.01%
29,150
– –
CDXS icon
160
Codexis
CDXS
$156M
$286K 0.01%
69,125
– –
MNK
161
DELISTED
Mallinckrodt plc
MNK
$256K 0.01%
35,048
– –
BDTX icon
162
Black Diamond Therapeutics
BDTX
$99.4M
$249K 0.01%
131,990
– –
ACET icon
163
Adicet Bio
ACET
$86.4M
$232K 0.01%
2,521
– –
HARP
164
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$193K 0.01%
25,991
– –
PCVX icon
165
Vaxcyte
PCVX
$7.73B
$187K 0.01%
5,000
– –
DTIL icon
166
Precision BioSciences
DTIL
$182M
$169K 0.01%
7,484
– –
FULC icon
167
Fulcrum Therapeutics
FULC
$283M
$167K 0.01%
58,537
– –
FUSN
168
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$164K 0.01%
43,394
– –
NKTX icon
169
Nkarta
NKTX
$154M
$103K ﹤0.01%
28,988
– –
SPPI
170
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$86K ﹤0.01%
114,670
– –
ORKA
171
Oruka Therapeutics
ORKA
$5.72B
$64.6K ﹤0.01%
2,705
– –
PRAX icon
172
Praxis Precision Medicines
PRAX
$8.52B
$60.7K ﹤0.01%
5,000
– –
CRBP icon
173
Corbus Pharmaceuticals
CRBP
$165M
$37.4K ﹤0.01%
5,143
-1
-0% -$4
YARW
174
Yarrow Bioscience, Inc. Common Stock
YARW
$25.3M
$23.2K ﹤0.01%
150
– –
NXGL icon
175
NexGel
NXGL
$3.9M
$5.52K ﹤0.01%
4,243
– –
4 5 6
7
8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Tekla Capital Management held 190 positions worth $2.63B, down 0.8% from $2.65B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q1 2023 filing shows 18 new, 27 increased, 27 reduced and 13 closed positions. Its largest new stake was Exelixis: 726,639 shares worth $14.1M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $47.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2023 buy was Exelixis: 726,639 shares worth $14.1M.
  • Tekla Capital Management added most to Elevance Health in Q1 2023, an estimated $47.3M increase.
  • Tekla Capital Management's biggest Q1 2023 reduction was Stryker, cutting an estimated $24.6M.
  • Tekla Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $47.2M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.63B portfolio in Q1 2023.
  • Tekla Capital Management opened 18 new positions and closed 13 in Q1 2023.
  • Tekla Capital Management's portfolio value fell 0.8% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q1 2023, filed 10 May 2023.